Polymorphisms in two genes, IL-1B and ACE, are associated with erythropoietin resistance in Korean patients on maintenance hemodialysis.
10.3858/emm.2008.40.2.161
- Author:
Kyung Hwan JEONG
1
;
Tae Won LEE
;
Chun Gyoo IHM
;
Sang Ho LEE
;
Ju Young MOON
Author Information
1. Department of Nephrology, College of Medicine, Kyung Hee University, Seoul 130-702, Korea. wonkid@chollian.net
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
end stage renal disease;
erythropoietin;
interleukin-1beta;
kidney failure, chronic;
peptidyl-dipeptidase A;
polymorphism, genetic
- MeSH:
Adult;
Aged;
*Drug Resistance;
Erythropoietin/*administration & dosage;
Female;
Humans;
Interleukin-1beta/*genetics;
Korea;
Male;
Middle Aged;
Peptidyl-Dipeptidase A/*genetics;
*Polymorphism, Genetic;
*Renal Dialysis
- From:Experimental & Molecular Medicine
2008;40(2):161-166
- CountryRepublic of Korea
- Language:English
-
Abstract:
Genetic polymorphisms may be linked to inter-individual differences in erythropoietin (EPO) resistance. We investigated the -511C/T polymorphism of the IL-1B gene and the I/D polymorphism of the ACE gene for any association with EPO resistance index (ERI) in maintenance hemodialysis patients (n=167). Because EPO responsiveness is multi-factorial, we also included other possible influences (age, sex, time on dialysis, ACE inhibitor or angiotensin receptor blocker use, ferritin, transferrin saturation, intact PTH, high sensitivity C-reactive protein, albumin, Kt/V, and presence of diabetes mellitus) on ERI in our analyses. Multiple regression analysis showed significant association of the IL-1B-511CC and ACE DD polymorphisms with ERI (P=0.038 and P=0.004 in the recessive model, respectively). The combination (C) of alleles of two loci showed that C1 (I-T) was significantly associated with ERI in the co-dominant and recessive models (P=0.005 and P=0.0001, respectively). Subjects who did not carry C1 showed significantly decreased ERI (10.10+/-5.15 IU/kg weight/g hemoglobin) compared to other study subjects (C1/C1 and C1/-; 12.97+/-4.90 and 15.12+/-7.43 IU/kg weight/g hemoglobin, respectively). Our study indicates that the IL-1B-511C/T and ACE I/D polymorphisms may be useful genetic markers of EPO requirement in hemodialysis patients. These findings might also provide a new perspective on therapeutic approaches to the treatment of end stage renal disease patients with anemia.
